Intraoperative red cell salvage during obstetric surgery in 50 Japanese women

Morikawa, Mamoru; Kuramoto, Akitaka; Nakayama, Masaki; Oguchi, Hidenori; Hasegawa, Masaaki; Funakoshi, Toru; Furukawa, Shoei; Hirayama, Emi; Kanagawa, Takeshi; Kaji, Tatsuru; Kasai, Mayumi; Konishi, Yasuhiro; Yamamoto, Shinichi; Itakura, Atsuo; Maeda, Makoto; Kobayashi, Takao; Minakami, Hisanori

doi:10.1016/j.ijgo.2014.09.008

Cited by 15 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Perioperative cell salvage has been used in obstetric surgery but is not widely established due to technology issues and a lack of staff training. 254 In obstetric haemorrhage, the routine use of cell salvage is associated with more salvaged blood returned to the patients, and the costs may be partly offset by reduced allogeneic blood use. 255 9.3.1.5.…”

Section: Should Cell Salvage Be Used In Obstetrics?mentioning

confidence: 99%

Management of severe perioperative bleeding

Kozek‐Langenecker

Ahmed

Afshari

et al. 2017

European Journal of Anaesthesiology

693

316

View full text Add to dashboard Cite

: The management of perioperative bleeding involves multiple assessments and strategies to ensure appropriate patient care. Initially, it is important to identify those patients with an increased risk of perioperative bleeding. Next, strategies should be employed to correct preoperative anaemia and to stabilise macrocirculation and microcirculation to optimise the patient's tolerance to bleeding. Finally, targeted interventions should be used to reduce intraoperative and postoperative bleeding, and so prevent subsequent morbidity and mortality. The objective of these updated guidelines is to provide healthcare professionals with an overview of the most recent evidence to help ensure improved clinical management of patients. For this update, electronic databases were searched without language restrictions from 2011 or 2012 (depending on the search) until 2015. These searches produced 18 334 articles. All articles were assessed and the existing 2013 guidelines were revised to take account of new evidence. This update includes revisions to existing recommendations with respect to the wording, or changes in the grade of recommendation, and also the addition of new recommendations. The final draft guideline was posted on the European Society of Anaesthesiology website for four weeks for review. All comments were collated and the guidelines were amended as appropriate. This publication reflects the output of this work.

show abstract

Section: Should Cell Salvage Be Used In Obstetrics?mentioning

confidence: 99%

Management of severe perioperative bleeding

Kozek‐Langenecker

Ahmed

Afshari

et al. 2017

European Journal of Anaesthesiology

693

316

View full text Add to dashboard Cite

show abstract

“…[5–7] In 2013, IOCS was legally introduced in obstetric operations in the UK. However, most available clinical evidence on IOCS is from case series and small controlled studies, [5,8–10] and a high-quality controlled trial with a large sample size is needed to further confirm its safety in this context. In addition, the effect of IOCS on ABT and coagulation factors for different degrees of bleeding remains uncertain.…”

Section: Introductionmentioning

confidence: 99%

How about “The effect of intraoperative cell salvage on allogeneic blood transfusion for patients with placenta accreta”?

Zeng

Huang

et al. 2018

Medicine

View full text Add to dashboard Cite

Intraoperative cell salvage (IOCS) for high-risk obstetric hemorrhage is now endorsed by a number of obstetric organizations. Most previous studies have focused on the safety of IOCS from case series and small controlled studies. Here, we describe the effect of IOCS on rates of allogeneic blood transfusion (ABT) under different degrees of bleeding during cesarean section in women with placenta accreta, which has seldom been reported in the literature.We conducted a retrospective analysis on the introduction of routine application of IOCS for the management of hemorrhage during cesarean section in women with placenta accreta. We identified 115 women, with prenatally diagnosed placenta accreta/increta/percreta before this change in practice, who served as controls, and 108 women who had IOCS applied during cesarean section.Compared with the control treatment, IOCS was significantly associated with a lower incidence of ABT (odds ratio, 0.179; 95% confidence interval, 0.098-0.328). Among the women with ≤3000 mL of bleeding, ABT was avoided in 80 (93.0%) of the 86 patients in the IOCS group, while 49 (50.0%) of the 98 controls required ABT. For women with an estimated blood loss >3000 mL, the reinfused IOCS blood may have helped prevent the need for ABT in 6 (28.6%) of the 21 patients, while all of the 17 controls required ABT. Subgroup analysis of coagulation function and the need for coagulation components showed no significant difference between the 2 groups (P > .05). Compared with the control treatment, IOCS was associated with a lower intraoperative volume of crystalloid (P < .01) and colloid infusion (P < .01) and a shorter length of postoperative hospital stay (P < .01) in patients with placenta accreta. In addition, there were no complications or adverse reactions in patients with placenta accreta who underwent IOCS.IOCS helped reduce the need for ABT and fluid transfusion in patients with placenta accreta and may be safe for use in obstetrics.

show abstract

“…No definite cases of amniotic fluid embolism have been reported so far and the risks of cell salvage in the obstetric population parallel those in the nonpregnant population. 93,94 Evidence level 4…”

mentioning

confidence: 99%